IRCT20230222057495N3
Recruiting
未知
The bioequivalence study of empagliflozin 10 mg tablets of Daram Yab Darou pharmaceutical company compared to the sample of empagliflozin 10 mg manufactured by Boehringer Ingelheim and Eli Lilly, Germany, on healthy volunteers.
Yab Daro Company0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- In the present study, no disease was investigated..
- Sponsor
- Yab Daro Company
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Be between 18 and 50 years old.
- •All candidates must be non\-smokers.
- •The Volunteer's body mass index (BMI) should be less than 30 kg for the square of their height in meters.
Exclusion Criteria
- •Volunteers with blood pressure less than 90/60 mm Hg or higher than 140/90 mm Hg.
- •Volunteers should refrain from smoking, consuming alcohol, caffeine (including coffee, cocoa, tea, cola drinks) 48 hours before the start of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Bioequivalence study of Empagliflozin ?? mg.IRCT20220111053692N18Tehran Chemie Pharmaceutical Company24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.IRCT20200105046010N49Pars Darou Pharm. Co.24
Not yet recruiting
Not Applicable
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26
Recruiting
Not Applicable
Bioequivalence study of Empagliflozin 25 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actoverco. Empagliflozin 25 mg tablet with brand Jardiance 25 mg tablet Boehringer..IRCT20180620040164N19Actover Pharmaceutical Co.24
Recruiting
Not Applicable
Bioequivalence of EmpaglifloziDetermination of plasma concentration of Empagliflozin 25 mg pharmaceutical product.IRCT20210201050197N5Shahid Beheshti University of Medical Sciences24